Ligand Targretin Gel NDA Supported By Capsule Data In Lieu Of 2nd Ph. III Trial
This article was originally published in Pharmaceutical Approvals Monthly
FDA accepted efficacy data on the capsule formulation of Ligand’s Targretin (bexarotene) as a replacement for a confirmatory Phase III study of Targretin gel 1%, according to FDA review documents.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class